Natera (NTRA) said Thursday it enrolled the first patients in a study evaluating its Signatera molecular residual disease test to guide treatment decisions in early-stage breast cancer.
The company said the study will enroll about 725 patients at 50 US sites and use Signatera to identify patients who may be able to defer standard of care.
Natera said the test aims to reduce over-treatment with certain standard therapy despite limited benefit and significant side effects.
Shares of Natera were down 2% in premarket activity Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments